Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Neurotech starts pivotal autism trial as US clearance and funding bolster NTI164 program

NTI: $0.018 -5.26% · MC: $31M

Neurotech International has dosed the first patient in its Phase 3 autism trial of NTI164, with all Australian sites initiated and up to 200 participants planned. The company also received US FDA clearance to begin a proposed clinical program and patent allowances, while securing a loan and placement commitments to support development; it says current funding is expected to last through the trial’s top-line data readout.

Source announcements: 2026-10-28 08:22 to 2026-10-28 08:22 Sydney time
Story updated 2026-10-28 08:26 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments